

## AGENDA

### ALABAMA MEDICAID AGENCY PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

November 14, 2012  
9:00 a.m. – 12:00 noon

---

1. Opening remarks.....Chair
2. Approval of August 8, 2012 P&T Committee Meeting minutes.....Chair
3. Pharmacy program update.....Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers' representatives  
(prior to each respective class review)
5. Pharmacotherapy class re-reviews...University of Massachusetts Medical School  
Clinical Pharmacy Services
  - First Generation Antihistamines
    - Ethanolamine Derivatives-AHFS 040404
    - Ethylenediamine Derivatives-AHFS 040408
    - Propylamine Derivatives-AHFS 040420
  - Estrogens-AHFS 681604
  - Alpha Glucosidase Inhibitors-AHFS 682002
  - Amylinomimetics-AHFS 682003
  - Biguanides-AHFS 682004
  - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors-AHFS 682005
  - Incretin Mimetics-AHFS 682006
  - Insulins-AHFS 682008
  - Meglitinide-AHFS 682016
  - Sulfonylureas-AHFS 682020
  - Thiazolidinediones-AHFS 682028
  - Antidiabetic Agents, Miscellaneous-AHFS 682092
  - Multivitamin Preparations: Prenatal Vitamins-AHFS 882800
6. Results of voting announced.....Chair
7. New business
8. Next meeting date: February 13, 2013
9. Adjourn

*The Alabama Medicaid Agency (AMA) is accredited by the Accreditation Council for Continuing Medicaid Education (ACCME) to provide continuing medical education for physicians. AMA is committed to the provision of CME that is balanced, objective and evidence-based. AMA adheres to the ACCME Essentials and Standards and accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity. Participants in the AMA CME programs are afforded the opportunity to provide feedback on the quality of individual programs.*